The clinical value of dynamic contrast-enhanced magnetic resonance imaging at 3.0T to detect prostate cancer. (October 2014)

• Record Type: Journal Article
• Authors: Zhang, Xuhui; Quan, Xianyue; Lu, Shilong; Huang, Fanheng; Yang, Jianming; Chan, Queenie; Lin, Ting
• Is Part Of: Journal of international medical research. Volume 42:Number 5(2014:Oct.)
• Page Start: 1077
• Page End: 1084
• Publication Date: 2014-10
• Subjects: Prostate cancer -- T2WI -- DCE-MRI -- Gleason score; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060514541827
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To compare dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and T2 -weighted imaging (T2 WI) at 3.0T for detection of prostate cancer. Methods: Patients with elevated prostate-specific antigen underwent T2 WI and DCE-MRI prior to prostate needle biopsy. The sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of T2 WI and DCE-MRI to diagnose prostate cancer were evaluated. The relationship between Gleason score and prostate cancer detection by DCE-MRI was evaluated. Results: Prostate adenocarcinoma was histopathologically confirmed in 44/75 patients. DCE-MRI had significantly higher sensitivity, accuracy and NPV than T2 WI. The detection rate of prostate cancer by DCE-MRI was significantly better for tumours with Gleason score 7–9 than for those Gleason score 4–6. Conclusion: DCE-MRI at 3.0T can significantly improve prostate cancer detection using simple visual diagnostic criteria, compared with T2 WI.